why choose us

First received: January 19, 2023

Clinical Trial: Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Opioid Use Disorder

Study Type: INTERVENTIONAL


Official Title: A Single-Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of SUBLOCADE at Alternative Injection Locations in Adults

Brief Summary: Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in 4 different quadrants of the abdomen for treatment of opioid use disorder (OUD).Injection locations are rotated to minimize irritation.Having 1 or more alternate injection sites is desirable for patients who may be taking SUBLOCADE for extended durations, based upon clinical response.The primary objective of this study is to assess the relative bioavailability of extended-release buprenorphine when…

Read more